Overview

12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder

Status:
Terminated
Trial end date:
2004-11-01
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of 12-O-tetradecanoylphorbol-13-acetate in treating patients with hematologic cancer or bone marrow disorder that has not responded to previous treatment.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University of Medicine and Dentistry of New Jersey
Collaborator:
National Cancer Institute (NCI)
Criteria
DISEASE CHARACTERISTICS:

- Histologically proven relapsed or refractory hematologic malignancy or bone marrow
disorder for which there is no standard curative therapy, including, but not limited
to:

- Myelodysplasia

- Multiple myeloma

- Myeloproliferative syndrome

- Chronic lymphocytic leukemia

- Aplastic anemia

- Non-Hodgkin's lymphoma

- Acute leukemia

- Hodgkin's lymphoma

- Chronic myelogenous leukemia

PATIENT CHARACTERISTICS:

Age:

- Over 18

Performance status:

- ECOG 0-2

Life expectancy:

- Greater than 1 month

Hematopoietic:

- Not specified

Hepatic:

- Bilirubin no greater than 1.5 times upper limit of normal (ULN)

- AST no greater than 3 times ULN

Renal:

- Creatinine no greater than 2.0 mg/dL

Cardiovascular:

- Cardiac ejection fraction greater than 40%

Pulmonary:

- FEV_1 greater than 50% predicted

Other:

- No active infection

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception during and for 10 weeks after study
participation

- No uncontrolled psychiatric or medical illness

PRIOR CONCURRENT THERAPY:

Biologic therapy:

- Greater than 3 weeks since prior biologic therapy

Chemotherapy:

- Greater than 3 weeks since prior chemotherapy and recovered

Endocrine therapy:

- Not specified

Radiotherapy:

- Not specified

Surgery:

- Not specified

Other:

- No other concurrent investigational agents